<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408979</url>
  </required_header>
  <id_info>
    <org_study_id>MgSO4</org_study_id>
    <nct_id>NCT01408979</nct_id>
  </id_info>
  <brief_title>Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia</brief_title>
  <acronym>MgSO4</acronym>
  <official_title>Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Materno Infantil Prof. Fernando Figueira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Materno Infantil Prof. Fernando Figueira</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnesium sulfate is the ideal drug for seizures prophilaxis in preeclampsia. The ideal
      duration of this treatment after delivery is still to be established. The hypothesis is that
      in stable patients a shorter course of treatment is possible without prejudice to the mother.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnesium sulfate (MgSO4) is certainly the ideal drug for prevention and control of eclamptic
      seizures. However, there is no consensus on the appropriate duration of prophylaxis with this
      anticonvulsant postpartum.The objective of the present study is to compare effectiveness of
      12 hours of magnesium sulfate versus 24 hours (standard treatment) in stable patients with
      preeclampsia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need to continue therapy for another 12 hours.</measure>
    <time_frame>24 hours</time_frame>
    <description>Defined as the need to continue therapy for another 12 hours, this will occur when after the first 12 hours of magnesium sulfate therapy the patient has severe hypertension, unsatisfactory diureses or has signs or symptoms of iminent eclampsia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>24 hours</time_frame>
    <description>Patients satisfaction with the duration of therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Severe Preeclampsia</condition>
  <arm_group>
    <arm_group_label>12 hours of magnesium sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will have magnesium sulfate administered for 12 hours after delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 hours of magnesium sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will have magnesium sulfate administered for 24 hours after delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate 12 hours</intervention_name>
    <description>Magnesium sulfate, 1g/h, (10% solution), for 12 hours</description>
    <arm_group_label>12 hours of magnesium sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate 24 hours</intervention_name>
    <description>Magnesium sulfate, 1g/h, (10% solution), for 24 hours</description>
    <arm_group_label>24 hours of magnesium sulfate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-eclampsia;

          -  Puerperium.

        Exclusion Criteria:

          -  Associated maternal diseases;

          -  Use of illicit drugs or other medications that might interfere with maternal
             hemodynamics;

          -  Contraindications to the use of magnesium sulfate: drug hypersensitivity, oliguria
             with urine output below 25ml/h; anuria (absent urine output), myasthenia gravis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melania M Amorim, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMIP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IMIP</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50.000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <last_update_submitted>August 20, 2012</last_update_submitted>
  <last_update_submitted_qc>August 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Materno Infantil Prof. Fernando Figueira</investigator_affiliation>
    <investigator_full_name>Leila Katz</investigator_full_name>
    <investigator_title>Obstetrical ICU obstetrical coordinator; MD , PhD</investigator_title>
  </responsible_party>
  <keyword>Severe preeclampsia</keyword>
  <keyword>magnesium sulfate</keyword>
  <keyword>anticonvulsivant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

